@davis
2 posts audited · 12 claims analysed
Science evidence grade
Based on 12 claims across 2 audits
5
Supported
42%
0
Overstated
0%
0
Misleading
0%
7
No Evidence
58%
Share this evidence grade
Claim-level evidence grades — not a character judgment. Methodology · Right of reply · Leaderboards
What @davis claims actually are
We separate claims into three buckets: backed by evidence, factually incorrect, and grey — like animal-only findings sold as human fact (e.g. BPC-157 “fixes Achilles” from rat studies).
Evidence-based
42%
5 claims
Claims that align with published human or clinical evidence at the stated strength.
Ex: “Semaglutide can reduce body weight in adults with obesity” — supported by large RCTs.
Factually incorrect
0%
0 claims
Claims that conflict with the evidence, invent certainty, or omit critical safety/context in a misleading way.
Ex: “Peptides have no side effects” — contradicts known adverse-event profiles.
Grey / overstated
58%
7 claims
Plausible direction but wrong certainty — animal-only data sold as human fact, dose/effect overstated, or no adequate published support yet.
Ex: “BPC-157 fixes Achilles tears” — often rests on rodent tendon models, not proven human Achilles repair trials.
Evidence mix
Share of audited claims in each bucket
Verdict detail
Grey splits into overstated (wrong certainty) vs no published support
Claims over time
Stacked by bucket as audits land — plus the running evidence grade
Gold line = running science evidence grade (Supported + ½ Overstated ÷ total claims).
Audit history(2 posts)
“can reta affect heart rate?”
All six claims lack verifiable support in peer-reviewed literature or registered clinical trials. Two citations (New England Journal of Medicine 2023; University of Copenhagen 2024 study) could not be validated. While retatrutide is a real GLP-1/GIP/glucagon receptor agonist under clinical development, the specific mechanistic and physiological claims about heart rate effects, pacemaker cell biology, and pathway targeting lack published evidence in standard databases. Without access to cited studies or underlying data, these claims cannot be assessed as scientifically supported.
“davistalkspepss on October 1, 2026”
The causal chain linking Retiface to facial puffiness via vasopressin remains entirely unvalidated. While Claims 3 and 6 rely on established mechanisms (GLP-1 effects on appetite; vasopressin-mediated water reabsorption), the intermediate steps (Claims 1, 2, 4, 5) lack direct scientific support. The claim that Retiface activates GLP-1 receptors is unproven, and the mechanistic link from appetite suppression → water intake reduction → hypernatremia → vasopressin release → facial edema is composed of disconnected assertions with no integrated evidence in the literature. Without validation of the foundational claims (Retiface identity, GLP-1 activation, and appetite-hydration coupling), the overall premise cannot be endorsed.
Audit another post from @davis
Paste their social post link to add a new audit